◎ Sugi Atlas

Atlas / Drug / Capivasertib

Capivasertib

drug
On this page

Also known as AZC5363Azd 5363Azd-5363AZD5363TruqapCAPIVASERTIB (AZD5363)

Summary

Capivasertib (CHEMBL2325741) is an approved small-molecule antineoplastic agent (ATC L01EX27) targeting AKT1, AKT2, and AKT3; indicated across 19 conditions including neoplasm and breast neoplasm; with CIViC clinical evidence for 39 variant-indication associations (e.g. AKT1 E17K in her2-receptor negative breast cancer).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: L01EX27
  • Targets: 3 (AKT1, AKT2, AKT3)
  • Indications: 19 conditions
  • Clinical trials: 55
  • Precision-oncology evidence (CIViC): 39 variant–indication associations
  • Chemistry: 428.9 Da · C21H25ClN6O2

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL2325741
NameCapivasertib
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID25227436
ChEBICHEBI:229222
ATCL01EX27
Molecular formulaC21H25ClN6O2
Molecular weight428.9
InChIKeyJDUBGYFRJFOXQC-KRWDZBQOSA-N

SMILES: C1CN(CCC1(C(=O)N[C@@H](CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4

IUPAC name: 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide

ChEBI definition: An aminopiperidine that is piperidine substituted by 7H-pyrrolo[2,3-d]pyrimidin-4-yl, amino, and [(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]aminocarbonyl groups at positions 1, 4, and 4, respectively. It is a pan-AKT kinase inhibitor used in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations.

Pharmacological roles (ChEBI): antineoplastic agent, EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor.

Also known as: AZC5363, Azd 5363, Azd-5363, AZD-5363, AZD5363, Capivasertib, Truqap, CAPIVASERTIB, AZD 5363, TRUQAP, CAPIVASERTIB (AZD5363)

Patent coverage: 843 distinct patent families (2,157 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 1,916 (89%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
AKT1AKT serine/threonine kinase 1Inhibition7.593.4%P31749
AKT2AKT serine/threonine kinase 2Inhibition8.12.6%P31751
AKT3AKT serine/threonine kinase 3Inhibition8.10.2%Q9Y243

Broader ChEMBL bioactivity targets: 29 (assay-derived). Sample: Proto-oncogene tyrosine-protein kinase receptor Ret, Serine/threonine-protein kinase AKT, 5’-AMP-activated protein kinase subunit gamma-1, RAC-beta serine/threonine-protein kinase, 5’-AMP-activated protein kinase subunit gamma-2, Serine/threonine-protein kinase D3, Mitogen-activated protein kinase kinase kinase 11, cAMP-dependent protein kinase catalytic subunit beta, Rho-associated protein kinase 2, Protein kinase C alpha type.

Bioactivity

ChEMBL activities: 55 potent at pChembl ≥ 5 of 56 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
AKT19.05IC500.9nMCHEMBL_ACT_26316467
AKT19IC501nMCHEMBL_ACT_26214208
AKT18.52IC503nMCHEMBL_ACT_12662154
AKT18.52IC503nMCHEMBL_ACT_22784728
AKT18.52IC503nMCHEMBL_ACT_25872909
AKT18.52IC503nMCHEMBL_ACT_25903352
AKT18.52IC503nMCHEMBL_ACT_25905435
AKT18.49IC503.2nMCHEMBL_ACT_27965993
AKT18.49IC503.2nMCHEMBL_ACT_28603706
AKT28.3IC505nMCHEMBL_ACT_26214223
AKT28.15IC507nMCHEMBL_ACT_22784729
AKT38.15IC507nMCHEMBL_ACT_22784730
AKT28.15IC507nMCHEMBL_ACT_25905436
AKT38.15IC507nMCHEMBL_ACT_25905437
AKT38.1IC508nMCHEMBL_ACT_12662098
AKT28.1IC508nMCHEMBL_ACT_12662126
AKT18.1IC508nMCHEMBL_ACT_23265862
AKT28.1IC508nMCHEMBL_ACT_25872912
AKT38.1IC508nMCHEMBL_ACT_25872915
AKT18.1IC508nMCHEMBL_ACT_25903353
AKT28.1IC508nMCHEMBL_ACT_25903354
AKT38.1IC508nMCHEMBL_ACT_26214238
AKT17.89IC5013nMCHEMBL_ACT_29055322
AKT17.59IC5025.43nMCHEMBL_ACT_19274123
AKT17.47IC5034nMCHEMBL_ACT_16589678
ROCK27.25IC5056nMCHEMBL_ACT_12662030
AKT37.24IC5057nMCHEMBL_ACT_29055324
AKT27.18IC5066nMCHEMBL_ACT_29055323
PRKACB6.62Kd239nMCHEMBL_ACT_17928705
PRKG16.53Kd297nMCHEMBL_ACT_17931902

Target pathways

Aggregated over 3 target gene(s): AKT1, AKT2, AKT3.

Top Reactome pathways

127 total, by targets touching each:

PathwayTargetsGenes
Apoptosis3AKT1, AKT2, AKT3
Intrinsic Pathway for Apoptosis3AKT1, AKT2, AKT3
Activation of BAD and translocation to mitochondria3AKT1, AKT2, AKT3
Activation of BH3-only proteins3AKT1, AKT2, AKT3
Signaling by ERBB23AKT1, AKT2, AKT3
PIP3 activates AKT signaling3AKT1, AKT2, AKT3
Developmental Biology3AKT1, AKT2, AKT3
Cytokine Signaling in Immune system3AKT1, AKT2, AKT3
Adaptive Immune System3AKT1, AKT2, AKT3
Downregulation of ERBB2:ERBB3 signaling3AKT1, AKT2, AKT3
Signal Transduction3AKT1, AKT2, AKT3
Cell Cycle3AKT1, AKT2, AKT3
Disease3AKT1, AKT2, AKT3
MTOR signalling3AKT1, AKT2, AKT3
Inhibition of TSC complex formation by AKT (PKB)3AKT1, AKT2, AKT3
Immune System3AKT1, AKT2, AKT3
Regulation of beta-cell development3AKT1, AKT2, AKT3
Signaling by VEGF3AKT1, AKT2, AKT3
AKT phosphorylates targets in the cytosol3AKT1, AKT2, AKT3
AKT phosphorylates targets in the nucleus3AKT1, AKT2, AKT3
Negative regulation of the PI3K/AKT network3AKT1, AKT2, AKT3
Membrane Trafficking3AKT1, AKT2, AKT3
Regulation of gene expression in beta cells3AKT1, AKT2, AKT3
AKT-mediated inactivation of FOXO1A3AKT1, AKT2, AKT3
Generic Transcription Pathway3AKT1, AKT2, AKT3
PI3K/AKT Signaling in Cancer3AKT1, AKT2, AKT3
Cellular responses to stress3AKT1, AKT2, AKT3
Transcriptional Regulation by TP533AKT1, AKT2, AKT3
Signaling by GPCR3AKT1, AKT2, AKT3
GPCR downstream signalling3AKT1, AKT2, AKT3

Dominant GO biological processes

GO termTargets
protein phosphorylation3
signal transduction3
insulin receptor signaling pathway3
positive regulation of cell migration3
intracellular signal transduction3
negative regulation of apoptotic process3
positive regulation of blood vessel endothelial cell migration3
negative regulation of PERK-mediated unfolded protein response3
positive regulation of endothelial cell proliferation2
glycogen biosynthetic process2
glucose metabolic process2
regulation of translation2
negative regulation of long-chain fatty acid import across plasma membrane2
positive regulation of glucose metabolic process2
regulation of cell migration2

Indications & clinical

Indications

19 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
neoplasm4MONDO:0005070EFO:0000616
breast neoplasm4MONDO:0021100EFO:0003869
adenocarcinoma2MONDO:0004970EFO:0000228
gastric adenocarcinoma2MONDO:0005036EFO:0000503
prostate adenocarcinoma2MONDO:0005082EFO:0000673
squamous cell carcinoma2MONDO:0005096EFO:0000707
non-small cell lung carcinoma2MONDO:0005233EFO:0003060
gastric neoplasm2MONDO:0021085MONDO:0001056
plasma cell myeloma2MONDO:0009693EFO:0001378
neoplasm of mature B-cells2MONDO:0004949EFO:0000096
triple-negative breast carcinoma2MONDO:0005494EFO:0005537
meningioma2MONDO:0016642MONDO:0850302
hereditary breast ovarian cancer syndrome1MONDO:0003582Orphanet:145
lymphoid neoplasm1MONDO:0005157EFO:0001642
tumor of uterus1MONDO:0021353EFO:0003859

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 55.

Phase distribution

PhaseTrials
PHASE221
PHASE117
PHASE39
PHASE1/PHASE28

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03997123PHASE3ACTIVE_NOT_RECRUITINGCapivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
NCT04305496PHASE3ACTIVE_NOT_RECRUITINGCapivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
NCT04493853PHASE3ACTIVE_NOT_RECRUITINGCapivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
NCT04862663PHASE3RECRUITINGCapivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT05348577PHASE3ACTIVE_NOT_RECRUITINGStudy of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT06635447PHASE3ACTIVE_NOT_RECRUITINGCapivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
NCT06764186PHASE3ACTIVE_NOT_RECRUITINGA Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain
NCT06982521PHASE3RECRUITINGPhase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT07281833PHASE3RECRUITINGPhase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
NCT01992952PHASE1/PHASE2ACTIVE_NOT_RECRUITINGFulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer
NCT02299999PHASE2ACTIVE_NOT_RECRUITINGSAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
NCT02465060PHASE2ACTIVE_NOT_RECRUITINGTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT02523014PHASE2RECRUITINGVismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
NCT02813135PHASE1/PHASE2RECRUITINGEuropean Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
NCT03660826PHASE2ACTIVE_NOT_RECRUITINGTesting the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
NCT03742102PHASE1/PHASE2ACTIVE_NOT_RECRUITINGA Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
NCT04439123PHASE2ACTIVE_NOT_RECRUITINGTesting AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
NCT05563220PHASE1/PHASE2RECRUITINGOpen-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
NCT05593497PHASE2RECRUITINGA Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
NCT05720260PHASE2RECRUITINGImmunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
NCT06607757PHASE2RECRUITINGCapivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer
NCT07175415PHASE1/PHASE2NOT_YET_RECRUITINGHEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
NCT07287917PHASE1/PHASE2RECRUITINGStudy of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
NCT07294677PHASE1/PHASE2RECRUITINGCApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL
NCT07426822PHASE2NOT_YET_RECRUITINGRash & Diarrhea Prophylaxis With Capivasertib
NCT02077569PHASE2COMPLETEDAKT Inhibitor in Oestrogen Positive Breast Cancer
NCT02117167PHASE2COMPLETEDSAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients
NCT02121639PHASE1/PHASE2COMPLETEDOpen Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy
NCT02423603PHASE2COMPLETEDPAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer
NCT02449655PHASE2TERMINATEDTrial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy
NCT02451956PHASE2COMPLETEDStudy of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy
NCT02525068PHASE2UNKNOWNA Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC
NCT02576444PHASE2TERMINATEDOLAParib COmbinations
NCT02664935PHASE2COMPLETEDNational Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
NCT03182634PHASE2UNKNOWNThe UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial
NCT03801369PHASE2TERMINATEDAMTEC IIT: Phase 2 Multiarm Study in TNBC
NCT05008055PHASE2COMPLETEDStudy of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT06613516PHASE2WITHDRAWNEffect of Capivasertib on ctDNA in ER Positive Breast Cancer
NCT02208375PHASE1ACTIVE_NOT_RECRUITINGmTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
NCT03772561PHASE1RECRUITINGPhase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies

Clinical evidence (CIViC)

Variant × indication × effect (39 predictive associations from 41 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
AKT1 E17KHer2-receptor Negative Breast CancerSensitivity/ResponseCapivasertib + FulvestrantCIViC AEID12181
PIK3CA C420RHer2-receptor Negative Breast CancerSensitivity/ResponseCapivasertib + FulvestrantCIViC AEID12183
PIK3CA E542KHer2-receptor Negative Breast CancerSensitivity/ResponseFulvestrant + CapivasertibCIViC AEID12184
PIK3CA E545AHer2-receptor Negative Breast CancerSensitivity/ResponseFulvestrant + CapivasertibCIViC AEID12185
PIK3CA E545DHer2-receptor Negative Breast CancerSensitivity/ResponseCapivasertib + FulvestrantCIViC AEID12186
PIK3CA E545GHer2-receptor Negative Breast CancerSensitivity/ResponseFulvestrant + CapivasertibCIViC AEID12189
PIK3CA E545KHer2-receptor Negative Breast CancerSensitivity/ResponseFulvestrant + CapivasertibCIViC AEID12188
PIK3CA E545QHer2-receptor Negative Breast CancerSensitivity/ResponseFulvestrant + CapivasertibCIViC AEID12187
PIK3CA G1049RHer2-receptor Negative Breast CancerSensitivity/ResponseCapivasertib + FulvestrantCIViC AEID12198
PIK3CA H1047LHer2-receptor Negative Breast CancerSensitivity/ResponseCapivasertib + FulvestrantCIViC AEID12197
PIK3CA H1047RHer2-receptor Negative Breast CancerSensitivity/ResponseFulvestrant + CapivasertibCIViC AEID12196
PIK3CA H1047YHer2-receptor Negative Breast CancerSensitivity/ResponseCapivasertib + FulvestrantCIViC AEID12195
PIK3CA M1043IHer2-receptor Negative Breast CancerSensitivity/ResponseCapivasertib + FulvestrantCIViC AEID12194
PIK3CA M1043VHer2-receptor Negative Breast CancerSensitivity/ResponseFulvestrant + CapivasertibCIViC AEID12193
PIK3CA Mutation OR PTEN Mutation OR AKT1 MutationBreast CancerSensitivity/ResponseCapivasertib + FulvestrantCIViC AEID12020
PIK3CA N345KHer2-receptor Negative Breast CancerSensitivity/ResponseCapivasertib + FulvestrantCIViC AEID12182
PIK3CA Q546EHer2-receptor Negative Breast CancerSensitivity/ResponseFulvestrant + CapivasertibCIViC AEID12190
PIK3CA Q546KHer2-receptor Negative Breast CancerSensitivity/ResponseCapivasertib + FulvestrantCIViC AEID12191
PIK3CA Q546PHer2-receptor Negative Breast CancerSensitivity/ResponseCapivasertib + FulvestrantCIViC AEID12192
PIK3CA R88QHer2-receptor Negative Breast CancerSensitivity/ResponseCapivasertib + FulvestrantCIViC AEID12034
AKT1 E17KCancerSensitivity/ResponseCapivasertibCIViC BEID3039 +1
PIK3CA MutationCancerSensitivity/ResponseCapivasertibCIViC BEID3040 +1
AKT1 D323GBreast CancerSensitivity/ResponseCapivasertibCIViC CEID10765
AKT1 E17KBreast CancerSensitivity/ResponseCapivasertibCIViC CEID709
AKT1 L52REndometrial CancerSensitivity/ResponseCapivasertibCIViC CEID10762
AKT2 L78_Q79insProstate CancerSensitivity/ResponseCapivasertibCIViC CEID10763
IRS2 AmplificationProstate CancerResistanceCapivasertibCIViC CEID10764
AKT1 F55YCancerSensitivity/ResponseARQ092 + CapivasertibCIViC DEID10766
AKT1 P68-C77dupCancerSensitivity/ResponseCapivasertibCIViC DEID10767
KDM5C Loss-of-function AND ( PIK3CA E545K OR PIK3CA H1047R OR PTEN Loss )Estrogen-receptor Positive Breast CancerSensitivity/ResponseCapivasertibCIViC DEID12936

+9 more predictive associations (showing top 30 by level).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

41 molecules share ≥1 primary target. Top 41 by shared-target count:

MoleculeSourceStatusShared targets
MIDOSTAURINChEMBLPhase 4 (approved)AKT1, AKT2, AKT3
AFURESERTIBChEMBLPhase 3AKT1, AKT2, AKT3
IPATASERTIBChEMBLPhase 3AKT1, AKT2, AKT3
LESTAURTINIBChEMBLPhase 3AKT1, AKT2, AKT3
MIRANSERTIBChEMBLPhase 2AKT1, AKT2, AKT3
MK-2206ChEMBLPhase 2AKT1, AKT2, AKT3
UPROSERTIBChEMBLPhase 2AKT1, AKT2, AKT3
AfatinibPubChemApprovedAKT1, AKT2, AKT3
belumosudilPubChemApprovedAKT1, AKT2, AKT3
BinimetinibPubChemApprovedAKT1, AKT2, AKT3
CrizotinibPubChemApprovedAKT1, AKT2, AKT3
dacomitinibPubChemApprovedAKT1, AKT2, AKT3
FostamatinibPubChemApprovedAKT1, AKT2, AKT3
IdelalisibPubChemApprovedAKT1, AKT2, AKT3
PazopanibPubChemApprovedAKT1, AKT2, AKT3
regorafenibPubChemApprovedAKT1, AKT2, AKT3
SelumetinibPubChemApprovedAKT1, AKT2, AKT3
TrametinibPubChemApprovedAKT1, AKT2, AKT3
FASUDILChEMBLPhase 3AKT1, AKT3
RUBOXISTAURINChEMBLPhase 3AKT2, AKT3
LAUROGUADINEChEMBLPhase 2AKT1, AKT2
SOTRASTAURINChEMBLPhase 2AKT1, AKT2
GefitinibPubChemApprovedAKT2, AKT3
MILTEFOSINEChEMBLPhase 4 (approved)AKT1
NICLOSAMIDEChEMBLPhase 4 (approved)AKT1
SUNITINIBChEMBLPhase 4 (approved)AKT2
ENZASTAURINChEMBLPhase 3AKT3
LINIFANIBChEMBLPhase 3AKT1
PERIFOSINEChEMBLPhase 3AKT1
QUERCETINChEMBLPhase 3AKT1
EDELFOSINEChEMBLPhase 2AKT1
ELLAGIC ACIDChEMBLPhase 2AKT1
KALAFUNGINChEMBLPhase 2AKT1
PF-04691502ChEMBLPhase 2AKT1
PICTILISIBChEMBLPhase 2AKT1
RUPITASERTIBChEMBLPhase 2AKT1
SULFAETHIDOLEChEMBLPhase 2AKT1
BelzutifanPubChemApprovedAKT2
CobimetinibPubChemApprovedAKT3
FedratinibPubChemApprovedAKT3
podofiloxPubChemApprovedAKT1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot